etanercept · Enbrel
Protein / enzyme therapeutic
Evidence outlook
Approved: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (5)
- Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
- Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).
- ENBREL is indicated for: • treatment of moderately to severely active rheumatoid arthritis (RA) in adults. Treatment is effective in reducing the signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function. ENBREL can be initiated in combination with methotrexate (MTX) in adult patients or used alone. • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years who have had an inadequate response to one or more disease-modifying...
- Enbrel: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis (adults and paediatric)
- Rheumatoid arthritis; Wyeth K.K. and Takeda
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00317499 NCT00317499 · Psoriatic Arthritis, Psoriasis Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference. Registry: NCT00317499 | 3 | — 2002-06 | ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001) | Reliable signal | link ↗ |
View 1 more trial
NCT02376790 NCT02376790 · Psoriatic Arthritis Participants were randomized to one of three treatment groups under full blinding of everyone involved, with a validated joint-response measure (ACR20) as the primary outcome. Both etanercept monotherapy and etanercept plus methotrexate significantly outperformed methotrexate alone at week 24 (65.0% and 60.9% response vs 50.7%, respectively; p=0.005 and p=0.029). Registry: NCT02376790 | 3 | Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and week 24) 2018-01-09 | ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (63)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (48)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (32)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (102)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (35)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (5)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other TNF-alpha drugs
adalimumab, adalimumab-aacf (Idacio), adalimumab-aaty (Yuflyma), adalimumab-adaz (Hyrimoz), adalimumab-adbm (Cyltezo) and 17 more. Compare all 23 TNF-alpha drugs
This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Etanercept (Enbrel): this drug | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | Reliable signal | NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001) | |
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | Reliable signal | NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | Reliable signal | NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3% NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19% | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Reliable signal | NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results). NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results). | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | Reliable signal | NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002 NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001 | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2% | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Zymfentra) | Approved(overall) | Monoclonal antibody | TNF-alpha | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ixekizumab (Taltz) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results). | |
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | Partial signal | No reviewed efficacy summary in this indication | |
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5) NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Icotrokinra (Icotyde) | Phase 3 | Peptide | IL-23 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-78934804 | Phase 3(overall) | Combination | IL-23 p19, TNF-alpha | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Netakimab | Phase 3 | Monoclonal antibody | IL-17 | Reliable signal | NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo. | |
| Sonelokimab | Phase 3 | Antibody-derived scaffold | IL-17A/F | Partial signal | NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled) | |
| Tirzepatide (Zepbound) | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Vunakizumab | Phase 3 | Monoclonal antibody | IL-17 | Partial signal | NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively | |
| Zasocitinib | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10374 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Hemay007 | Phase 1(overall) | Small molecule | TNF-alpha | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| LPX-TI641 | Phase 1 | Small molecule | TIM receptor (Treg-expanding) | not yet graded | No reviewed efficacy summary in this indication | |
| S-4321 | Phase 1 | Multispecific antibody | PD-1 / FcγRIIb (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| SOR102 | Phase 1(overall) | Biologic (subtype unspecified) | TNF-alpha, IL-23 p19 | Weak signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
12 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Enbrel (etanercept) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.